As William Lyon Homes (WLH) Share Value Declined, Second Curve Capital Has Raised by $1.49 Million Its Stake; Bvf Has Lowered Its Chemocentryx (CCXI) Position by $5.02 Million; Valuation Rose




August 30, 2018 – By Jimmy Cauthen

William Lyon Homes (NYSE:WLH) Logo

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 5.09% based on its latest 2018Q1 regulatory filing with the SEC. Bvf Inc sold 386,100 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 7.20M shares of the health care company at the end of 2018Q1, valued at $97.94M, down from 7.59 million at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $649.13 million market cap company. The stock increased 0.98% or $0.125 during the last trading session, reaching $12.885. About 41,878 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 30, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En

Second Curve Capital Llc increased its stake in William Lyon Homes (WLH) by 8.46% based on its latest 2018Q1 regulatory filing with the SEC. Second Curve Capital Llc bought 55,000 shares as the company’s stock declined 7.70% with the market. The hedge fund held 705,500 shares of the homebuilding company at the end of 2018Q1, valued at $19.39M, up from 650,500 at the end of the previous reported quarter. Second Curve Capital Llc who had been investing in William Lyon Homes for a number of months, seems to be bullish on the $748.81M market cap company. The stock decreased 0.47% or $0.0925 during the last trading session, reaching $19.7175. About 113,175 shares traded. William Lyon Homes (NYSE:WLH) has risen 6.93% since August 30, 2017 and is uptrending. It has underperformed by 5.64% the S&P500. Some Historical WLH News: 25/05/2018 – WILLIAM LYON HOMES – CO, UNIT ENTERED INTO A NEW CREDIT AGREEMENT PROVIDING FOR UNSECURED REVOLVING CREDIT FACILITY OF UP TO $325.0 MLN – SEC FILING; 08/05/2018 – William Lyon Homes 1Q Net $8.33M; 09/03/2018 – William Lyon Homes Completes Acquisition Of RSI Communities, A Southern California And Texas Based Homebuilder; 08/05/2018 – William Lyon Homes 1Q Adj EPS 27c; 08/05/2018 – WILLIAM LYON HOMES – DOLLAR VALUE OF HOMES IN BACKLOG WAS $752.1 MLN AS OF MARCH 31, 2018; 08/05/2018 – WILLIAM LYON HOMES – QTRLY HOME SALES REVENUE OF $372.4 MLN, UP 44%; 25/05/2018 – WILLIAM LYON HOMES – NEW FACILITY REPLACES CO’S PREVIOUS $170 MLN REVOLVING CREDIT FACILITY; 06/03/2018 – WILLIAM LYON HOMES – TO USE PROCEEDS FROM OFFERING, $200.0 MLN CASH FROM CERTAIN LAND BANKING ARRANGEMENTS, CASH, TO FINANCE RSI ACQUISITION; 29/03/2018 – William Lyon Closes Above 50-Day Moving Average: Technicals; 08/05/2018 – William Lyon Homes 1Q EPS 21c

Among 5 analysts covering William Lyon Homes (NYSE:WLH), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. William Lyon Homes had 18 analyst reports since August 29, 2015 according to SRatingsIntel. The stock of William Lyon Homes (NYSE:WLH) earned “Outperform” rating by Wedbush on Tuesday, July 10. The company was initiated on Tuesday, June 19 by Citigroup. Citigroup downgraded the stock to “Hold” rating in Thursday, January 4 report. The company was downgraded on Thursday, January 12 by JMP Securities. Zacks upgraded the shares of WLH in report on Saturday, August 29 to “Sell” rating. The firm has “Hold” rating given on Thursday, September 17 by Zacks. The company was maintained on Wednesday, November 1 by UBS. The company was initiated on Tuesday, December 6 by Wedbush. Zacks upgraded William Lyon Homes (NYSE:WLH) on Friday, September 4 to “Hold” rating. The stock of William Lyon Homes (NYSE:WLH) has “Neutral” rating given on Thursday, August 2 by Citigroup.

Second Curve Capital Llc, which manages about $545.33M and $259.77M US Long portfolio, decreased its stake in Zions Bancorporation (NASDAQ:ZIONW) by 235,300 shares to 258,052 shares, valued at $5.24 million in 2018Q1, according to the filing. It also reduced its holding in Meta Finl Group Inc (NASDAQ:CASH) by 55,000 shares in the quarter, leaving it with 293,132 shares, and cut its stake in Tristate Capital Holdings Inc (NASDAQ:TSC).

Bvf Inc, which manages about $999.89 million and $986.48M US Long portfolio, upped its stake in Forward Pharma A/S by 1.30M shares to 4.76M shares, valued at $10.32M in 2018Q1, according to the filing. It also increased its holding in Immune Design Corp (NASDAQ:IMDZ) by 2.64 million shares in the quarter, for a total of 4.11M shares, and has risen its stake in Pieris Pharmaceuticals Inc.

Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. ChemoCentryx had 10 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was downgraded by JP Morgan to “Neutral” on Tuesday, August 14. The firm earned “Overweight” rating on Tuesday, March 13 by JP Morgan. As per Tuesday, August 8, the company rating was maintained by Cowen & Co. The stock has “Sell” rating by Zacks on Monday, September 21. The firm has “Mkt Outperform” rating by JMP Securities given on Tuesday, February 21. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by JMP Securities on Thursday, August 10. The firm has “Sell” rating by Zacks given on Thursday, September 3.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on November, 6. They expect $-0.25 EPS, down 92.31% or $0.12 from last year’s $-0.13 per share. After $-0.14 actual EPS reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 78.57% negative EPS growth.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It fall, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. Bank & Trust Of Montreal Can owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 10,828 shares. Northern Tru reported 276,280 shares. New York-based Financial Bank Of Mellon has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein Ltd Partnership accumulated 40,100 shares or 0% of the stock. Missouri-based American Century has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). J Goldman And Ltd Partnership holds 39,000 shares. Ellington Mgmt Group Llc owns 25,200 shares. 637 are held by Meeder Asset. Invesco Limited stated it has 49,265 shares. Bridgeway holds 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 50,246 shares. Thompson Davis And Com holds 625 shares. Jpmorgan Chase And accumulated 67,861 shares. 15,708 are held by Jacobs Levy Equity Mgmt. Bnp Paribas Arbitrage has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 38,188 were reported by California State Teachers Retirement Systems.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights” on August 09, 2018, also Seekingalpha.com with their article: “ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q2 2018 Results – Earnings Call Transcript” published on August 10, 2018, Seekingalpha.com published: “ChemoCentryx 2018 Q2 – Results – Earnings Call Slides” on August 10, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals …” published on August 20, 2018 as well as Nasdaq.com‘s news article titled: “ChemoCentryx to Present at Two Upcoming Investor Conferences” with publication date: August 22, 2018.

Since May 1, 2018, it had 0 buys, and 12 insider sales for $7.89 million activity. KANAYA SUSAN M sold $15,709 worth of stock or 1,366 shares. 10,857 shares valued at $152,028 were sold by Schall Thomas J. on Thursday, June 28.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *